Story perspectives

FDA Recalls Prazosin Over Cancer Risk for 510,000 Patients

11/10/2025

50 5

Summary

Story summary

The U.S. Food and Drug Administration (FDA) has recalled Teva Pharmaceuticals' prazosin due to elevated nitrosamine levels, affecting over 580,000 capsules.
Prazosin is prescribed to about 510,000 patients annually for PTSD and high blood pressure.
The recall, announced on October 7, 2025, notes nitrosamine-related cancer risks and that India-made generics have a 54.3% higher risk of serious adverse events than U.S.-made products, and patients should consult their doctors before discontinuing use.

1 of 1

Story summary

The U.S. Food and Drug Administration (FDA) has recalled Teva Pharmaceuticals' prazosin due to elevated nitrosamine levels, affecting over 580,000 capsules.
Prazosin is prescribed to about 510,000 patients annually for PTSD and high blood pressure.
The recall, announced on October 7, 2025, notes nitrosamine-related cancer risks and that India-made generics have a 54.3% higher risk of serious adverse events than U.S.-made products, and patients should consult their doctors before discontinuing use.